Shares of Bio-Techne Corp. slipped 4.01% to $48.81 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 1.01% to 6,699.38 and the Dow ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Bio-Techne (NASDAQ:TECH) will release its quarterly earnings report on Wednesday, 2024-10-30. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Bio-Techne to report ...

Bio-Techne (TECH) has expanded its COMET spatial biology platform with new SPYRE Focus Panels, SPYRE Amplification Kits, and updated HORIZON image analysis tools, a product move that matters for the ...

Bio-Techne Corp. TECH has launched a highly sensitive ESR1 mutation monitoring assay through its Asuragen brand. ESR1 gene mutations are known to be linked to hormone receptor-positive (HR+) ...

(RTTNews) - Gemini Bioproducts, LLC, a supplier of cell culture reagents and process liquids and healthcare private equity firm BelHealth Investment Partners, LLC announced acquisition of selected ...

Shares of Bio-Techne Corp. TECH rallied 2.14% to $52.04 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.11% ...

Bio-Techne (NASDAQ:TECH) will release its quarterly earnings report on Wednesday, 2025-11-05. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Bio-Techne to report ...

(Reuters) - Bio-Techne missed Wall Street expectations for first-quarter profit on Tuesday, as a persisting funding crunch among its biotech clients weighed on demand for its diagnostic products and ...

MINNEAPOLIS, April 26, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Novomol-Dx, a molecular diagnostics company, are pleased to announce the development of Bio-Marker Pathfinder (BMP ...

MINNEAPOLIS , Feb. 16, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced that the Ella benchtop ...

The DCF model implemented in this article suggests that Bio-Techne is overvalued by 34.53%. Bio-Techne has allocated significant financial resources to capex. Due to these resources, its revenues ...